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ABSTRACT
Vaccination against influenza during pregnancy provides direct protection to pregnant women and indirect
protection to their infants. Trivalent inactivated influenza vaccines (IIV3s) are safe and effective during
pregnancy, but quadrivalent inactivated influenza vaccines (IIV4s) have not been evaluated in pregnant
women and their infants. Here, we report the results of a randomized phase IV study to evaluate the
immunogenicity and safety of IIV4 vs. IIV3 in pregnant women. Participants aged ≥18 years at weeks 20 to 32
of gestation were randomly assigned in a 2:1 ratio to receive a single dose of IIV4 (n = 230) or IIV3 (n = 116).
Between baseline and 21 days after vaccination, hemagglutination inhibition (HAI) antibody titers increased
in both groups by similar magnitudes for the two influenza A strains and single B strain common to IIV4 and
IIV3. For the additional B strain in IIV4, HAI titers were higher in IIV4 recipients than IIV3 recipients (post-/pre-
vaccination geometric mean titer ratio, 6.3 [95% CI: 5.1 − 7.7] vs. 3.4 [95% CI: 2.7 − 4.3]). At delivery, in both
groups, HAI antibody titers for all strains were 1.5 − 1.9-fold higher in umbilical cord blood than in maternal
blood, confirming active transplacental antibody transfer. Rates of solicited and unsolicited vaccine-related
adverse events inmothers were similar between the two groups. Live births were reported for all participants
and there were no vaccine-related adverse events in newborns. These results suggest IIV4 is as safe and
immunogenic as IIV3 in pregnant women, and that maternal immunization with IIV4 should protect new-
borns against influenza via passively acquired antibodies.
ARTICLE HISTORY
Received 5 June 2019
Revised 20 August 2019
Accepted 6 September 2019
KEYWORDS
Immunization; influenza
vaccines; newborn infant;
pregnancy; safety; seasonal
influenza; transplacental
antibody transfer;
vaccination
Introduction
Pregnant women and young infants are among the population
subgroups at greatest risk of severe illness, complications, and
death from influenza.1,2 Hospital admissions for influenza
illness are more frequent among pregnant women than non-
pregnant women,3,4 and influenza in young infants frequently
leads to hospitalization,5 bacterial co-infections,6,7 and
a higher mortality rate than in older children.8 Severe influ-
enza illness during pregnancy has also been associated with
preterm birth and fetal death in the 2009 influenza A/H1N1
pandemic.9
Maternal vaccination during pregnancy is considered the
most effective strategy to protect pregnant women and new-
born infants against influenza.1 The World Health
Organization (WHO)1 and other advisory bodies10–12 recom-
mend that pregnant women are prioritized for influenza vac-
cination, since this provides both direct protection to
pregnant women and indirect protection to their infants via
transplacental maternal antibody transfer.2,13–16 This strategy
is especially important for preventing influenza illness in
infants aged less than 6 months because influenza vaccines
are not licensed for use in this age group.
Inactivated influenza vaccines have been shown to be safe,
immunogenic, and effective during pregnancy in several
randomized controlled studies.13–15,17 Importantly, vaccination
was shown to reduce the incidence of laboratory-confirmed
influenza cases in pregnant women and their newborns by
around 50%.13–16,18,19 Studies have also identified reduced rates
of influenza-related hospitalization among infants born to
women vaccinated against influenza during pregnancy.19–21
However, in many countries, few pregnant women receive influ-
enza vaccines, often due to low awareness of the risks posed by
the disease and concerns about the safety and efficacy of influ-
enza vaccination during pregnancy.22
Until recently, most influenza vaccines have been trivalent,
containing antigens from two influenza A subtypes (H1N1
and H3N2) and one influenza B lineage virus.1,23 However,
since the 1980s, two antigenically distinct influenza B lineages
have co-circulated globally, which has complicated the selec-
tion of the correct B lineage for each new influenza season.24
Global data indicate that differences frequently occur between
the trivalent vaccine and the predominant circulating
B lineage strains, which has resulted in suboptimal protection
in several previous influenza seasons.25–27 To help ensure
protection against influenza B, quadrivalent inactivated influ-
enza vaccines (IIV4s), which contain the two A strains and
a strain from each B lineage, have been developed and are
generally replacing trivalent inactivated influenza vaccines
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(IIV3s) worldwide.24 Although there are no specific data on
influenza B infection in pregnant women, influenza B is
known to cause similar morbidity to influenza A across dif-
ferent populations and age groups.28 Vaccination during preg-
nancy with IIV4 instead of IIV3 would therefore extend
protection to cover both circulating B lineages in pregnant
women and newborns.
Whereas vaccination during pregnancy with IIV3s has
been shown safe, effective, and to result in transplacental
maternal antibody transfer,13–15 IIV4s have not been evalu-
ated in pregnant women and their infants. Here, we report the
immunogenicity and safety of an IIV4 in pregnant women, as
well as birth outcomes and transplacental transfer of vaccine-
induced antibodies.
Patients and methods
Study design
This was a Phase IV, randomized, blind observer, controlled,
multi-center study conducted in pregnant women in Finland
between September, 2017 and June, 2018 (EudraCT number:
2016-004763-40).
During the study enrollment period, the National
Immunization Program of Finland offered vaccination with
IIV3 free of charge for pregnant women at any stage of
pregnancy.29 This led to a lower than expected rate of enrollment
and, consequently, the required study power was not achieved
for the original primary (non-inferiority of IIV4 immune
responses vs. IIV3) and secondary (superiority of IIV4 immune
response against the additional B strain) immunogenicity objec-
tives. The study protocol was amended by replacing the immu-
nogenicity objectives by a description of the immune response.
The revised primary objectives of the study were (a) to
describe the immune response and (b) to describe the safety
of one dose of IIV4 (VaxigripTetra, Sanofi Pasteur) or IIV3
(Vaxigrip, Sanofi Pasteur) 21 days after vaccination in preg-
nant women. Secondary objectives were to evaluate the trans-
placental transfer of antibody from mother to newborn from
the cord blood after one dose of IIV4 or IIV3, and to evaluate
the safety profile of IIV4 and IIV3 in pregnant women and in
terms of birth outcome. The study was approved by the
national ethics committee and conducted in accordance with
the Declaration of Helsinki, Good Epidemiological Practice,
and national regulations. All participants provided their writ-
ten informed consent before inclusion.
Participants
The study included pregnant women aged ≥18 years at 20 to
32 weeks of pregnancy. This gestational age was chosen to
assess transplacental antibody transfer at birth. Potential sub-
jects were excluded if they had received any vaccine within
4 weeks before study vaccination; already been vaccinated
against influenza in the 2017 − 2018 season; experienced
pregnancy complications during the current pregnancy; or
had a chronic illness that, in the opinion of the investigator,
might interfere with the study assessments. Further exclusion
criteria are provided in the Supplementary Materials.
Vaccines
The study used the WHO-recommended 2017–2018 Northern
Hemisphere formulations of IIV4 and IIV3. Both vaccines were
inactivated, split-virion, thimerosal-free, and were provided in
pre-filled syringes of 0.5 ml. IIV3 contained 15 µg hemagglutinin
per strain of A/Michigan/45/2015 (H1N1)pdm09-like virus, A/
Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/
2008-like virus (B/Victoria lineage). IIV4 contained 15 µg
hemagglutinin of each of the above strains plus 15 µg hemagglu-
tinin of B/Phuket/3073/2013-like virus (B/Yamagata lineage).
Study conduct
Participants were randomly assigned in a 2:1 ratio to receive
a single dose (0.5 ml) of IIV4 or IIV3 by intramuscular
injection. Randomization was performed using the permuted
block method and scratchable randomization lists were used
at each site to communicate which vaccine was to be injected.
The study was conducted in a blind observer manner, where
neither the participants nor the investigators responsible for
safety assessment knew which vaccine was administered.
Blood samples were taken from the study participants at
baseline (day 0) and 21 days after vaccination to determine
hemagglutination inhibition (HAI) antibody titers. To study
the transfer of maternal antibodies, blood samples were also
taken from the participants within 4 days of delivery and from
the umbilical cord on the day of delivery.
Immunogenicity assessments
Anti-hemagglutinin antibody levels were measured in the
participants before vaccination (day 0) and 21 days after the
last vaccination, and in the participants and umbilical cord
blood after delivery, by HAI assay as described previously.30
Geometric mean titers (GMTs), the geometric mean of the
individual ratios of post-vaccination vs. pre-vaccination
(day 0) titers, percentages of individuals with titers ≥1:40,
and seroconversion or significant increase in HAI titer were
calculated. Seroconversion was defined as a pre-vaccination
HAI titer <1:10 and a post-vaccination titer ≥1:40; and
a significant increase as a pre-vaccination HAI titer ≥1:10
and ≥4-fold increase in post- vs. pre-vaccination HAI titer.
Safety assessments
Safety was assessed according to International Conference on
Harmonization guidelines.31 Immediate unsolicited adverse
events (AEs) were defined as those occurring within 30 min
following vaccination. Subjects recorded information about soli-
cited reactions in a diary card for up to 7 days after vaccination,
and about unsolicited AEs up to 21 days after vaccination. Any
serious AEs were reported to investigators throughout the study,
from inclusion until delivery. The newborn baby underwent
a physical examination after delivery. Any complications during
pregnancy or delivery were considered as AEs, and in some cases
were considered serious AEs (e.g., spontaneous abortions, fetal
death, stillbirth, and congenital anomalies reported in the baby).
Investigators assessed unsolicited AEs and serious AEs as
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unrelated or possibly related to the vaccination. AEs were coded
with Medical Dictionary for Regulatory Activities (MedDRA)
terminology (version 19.0).
Sample size
Under the original trial protocol, with 486 subjects planned for
enrollment in the IIV4 group and 243 in the IIV3 group, the study
was planned to have an overall power of >80% for the original
non-inferiority and superiority immunogenicity endpoint ana-
lyses. Following the low rate of enrollment, the study protocol
was amended to make the immunogenicity objectives descriptive
only, and so recalculating the sample size was not required.
Statistical analysis
All analyses were descriptive. 95% confidence intervals (CIs)
were calculated using SAS® version 9.4 (SAS Institute, Cary,
NC, USA). Missing or incomplete data were not replaced,
with the exception that all HAI titers under the lower limit
of quantitation (10) were assigned a value of 5 and all HAI
titers above the upper limit of quantitation (10,240) were
assigned a value of 10,240. Immunogenicity was analyzed in
all eligible subjects who were vaccinated according to protocol
and who had valid serology results. Safety was analyzed in all
subjects who received a study vaccine.
Results
Study population
The study enrolled 346 subjects in Finland between September 15,
2017 and January 26, 2018. Enrollmentwas stopped on January 26,
2018, before reaching the number of subjects to achieve the study
power for the original primary (non-inferiority of IIV4 immune
responses vs. IIV3) and secondary (superiority of IIV4 immune
response against the additional B strain) immunogenicity objec-
tives. This was due to an unforeseen increase in free-of-charge
IIV3 vaccination among pregnant women under the Finnish
influenza vaccination program.
By the end of the enrollment period, 230 subjects had been
randomized to receive IIV4 and 116 had been randomized to
receive IIV3 (Figure 1). The study ended on June 14, 2018 and
was completed by all subjects except for two vaccinated with
IIV4 (one voluntarily withdrawal and one due to noncompli-
ance with the study protocol [missing visit] because of pre-
term delivery, which was considered unrelated to the vaccine)
and one vaccinated with IIV3 (lost to follow-up).
Subject demographics were similar between the two groups:
the median age was 32.1 years (range: 20.3 − 44.3 years) for the
women vaccinated with IIV4 and 30.7 years (range:
20.5 − 42.5 years) for those vaccinated with IIV3, and the
median gestational age at enrollment was 25 weeks (interquar-
tile range [IQR]: 22 − 29 weeks) for the IIV4 recipients and
24 weeks (IQR: 21 − 27 weeks) for the IIV3 recipients.
Immunogenicity
Baseline HAI antibody titers for all vaccine strains were similar
between the pregnant women vaccinated with IIV4 and those
vaccinated with IIV3 (Table 1). At 21 days after vaccination, HAI
antibody titers had increased in IIV4 recipients for all vaccine
strains by 3.8-fold to 8.6-fold from baseline titers. The increase in
HAI antibody titers was similar in IIV3 recipients for the A/
H1N1, A/H3N2, and B/Victoria strains common to both vac-
cines (post-/pre-vaccination GMT ratios: 5.3 − 9.6). However,
Figure 1. Study design and disposition of participants. Pregnant women aged ≥18 years at 20 to 32 weeks of pregnancy were randomly assigned 2:1 to receive IIV4
or IIV3 by intramuscular injection.
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IIV4 HAI titers were higher than IIV3 titers for the B/Yamagata
strain (GMT ratios: 6.3 [95% CI: 5.1 − 7.7] vs. 3.4 [95% CI:
2.7 − 4.3]). At least 95.8% of IIV4 recipients and 94.5% of IIV3
recipients had titers ≥1:40 against individual vaccine strains at
21 days after vaccination. Rates of seroconversion/significant
increase in titers were 38% to 61% in IIV4 recipients and 41%
to 62% in IIV3 recipients for the three common vaccine strains.
For B/Yamagata, more participants vaccinated with IIV4 sero-
converted or had significant increases in titers than those vacci-
nated with IIV3 (59.7% [95% CI: 52.9 − 66.3%] vs. 38.5% [95%
CI: 29.4 − 48.3%]).
At delivery, HAI antibody titers for the A/H1N1 strain
were almost twice as high in the umbilical cord blood as in
the maternal blood in both groups (1.9-fold higher in the IIV4
group, 1.8-fold higher in the IIV3 group) and were between
1.5 and 1.7 times as high for the A/H3N2 strain and two
B-lineage strains (Figure 2). The cord blood to maternal blood
HAI GMT ratios were similar between the IIV4 and IIV3
groups for all four vaccine strains.
Safety
The proportions of subjects reporting solicited reactions and
unsolicited vaccine-related AEs were similar between the two
vaccine groups (Table 2). Injection site reactions were reported
by most subjects vaccinated with IIV4 (90.0%) and IIV3
(80.9%). These were typically mild (grade 1) in intensity and
resolved within 3 days. Pain at the injection site was more
frequently reported by subjects vaccinated with IIV4 than
those vaccinated with IIV3 (88.7% [95% CI: 83.9 − 92.5%] vs.
76.5% [95% CI: 67.7 − 83.9%]) (Supplemental Table 1). The
most frequently reported solicited systemic reaction in the two
vaccine groups was headache. The most common vaccine-
related unsolicited AEs were injection site pruritus, fatigue,
and oropharyngeal pain (Supplemental Table 1). None of the
subjects reported grade 3 (severe) solicited reactions or unsoli-
cited vaccine-related AEs.
Two serious AEs were experienced within 21 days of vac-
cination (one hospitalization for pneumonia and one hospi-
talization for pre-eclampsia), although neither was considered
vaccine-related. No immediate unsolicited AEs were reported
and none of the participants had AEs leading to discontinua-
tion from the study.
Birth outcomes
All birth outcomes reported were live births. One subject
vaccinated with IIV4 and three subjects vaccinated with
IIV3 gave birth to twins. Baby birth weights and heights,
and the proportion of participants having vaginal and
C-section deliveries were also similar between the two groups.
Six congenital abnormalities were reported in babies of
IIV4-vaccinated mothers (2.6%) and five in babies of IIV3-
vaccinated mothers (4.2%), most of which were hip dysplasias.
There were no vaccine-related adverse events in newborns.
Discussion
By including strains from both circulating B lineages, IIV4s
extend the protection provided by IIV3s against influenza.
However, the safety and efficacy of IIV4s in pregnant women –
a group prioritized for vaccination1 – has not been previously
evaluated. The results from this randomized study showed that
IIV4 had similar immunogenicity to IIV3 and was well tolerated
in pregnant women vaccinated during the second or third tri-
mester of pregnancy. In addition, high HAI antibody titers were
found in the cord blood after delivery, suggesting maternal
immunization conferred protection to newborns via transpla-
cental antibody transfer.
Consistent with studies in non-pregnant adults,30,32,33 IIV4
induced similar HAI antibody titers to IIV3 in pregnant women
for the three common vaccine strains, and higher HAI titers for
the additional B lineage strain. Baseline HAI antibody titers for
A/H1N1 and B/Yamagata were high in the study population.
The high baseline A/H1N1 titers might be explained by previous
Table 1. HAI antibody responses.
A/H1N1 A/H3N2 B/Victoria B/Yamagata
Measure Day IIV4 IIV3 IIV4 IIV3 IIV4 IIV3 IIV4 IIV3a
N - 216 109 216 109 216 109 216 109
HAI GMT (95% CI) 0 138
(114 − 166)
121
(88.4 − 166)
39.6
(32.2 − 48.6)
40.0
(29.4 − 54.5)
67.1
(55.2 − 81.4)
72.5
(54.7 − 96.1)
159
(131 − 193)
155
(120 − 202)
21 525
(466 − 592)
638
(529 − 769)
341
(286 − 407)
369
(283 − 483)
568
(496 − 651)
697
(569 − 855)
993
(870 − 1134)
529
(415 − 674)
HAI titer ≥1:40, % (95% CI) 0 86.1
(80.8 − 90.4)
78.0
(69.0 − 85.4)
55.1
(48.2 − 61.8)
53.2
(43.4 − 62.8)
69.4
(62.8 − 75.5)
65.1
(55.4 − 74.0)
85.2
(79.7 − 89.6)
83.5
(75.2 − 89.9)
21 99.5
(97.4 − 100)
100
(96.7 − 100)
95.8
(92.2 − 98.1)
94.5
(88.4 − 98.0)
100
(98.3 − 100)
99.1
(95.0 − 100)
100
(98.3 − 100)
97.2
(92.2 − 99.4)
GMT ratiob (95% CI) 21/0 3.8
(3.1 − 4.7)
5.3
(3.7 − 7.6)
8.6
(6.9 − 10.9)
9.2
(6.6 − 13.0)
8.5
(6.8 − 10.6)
9.6
(6.9 − 13.4)
6.3
(5.1 − 7.7)
3.4
(2.7 − 4.3)
Seroconversion or significant
increasec, % (95% CI)
21/0 38.0
(31.5 − 44.8)
41.3
(31.9 − 51.1)
59.3
(52.4 − 65.9)
62.4
(52.6 − 71.5)
61.1
(54.3 − 67.7)
60.6
(50.7 − 69.8)
59.7
(52.9 − 66.3)
38.5
(29.4 − 48.3)
Values are for all subjects completing the study according to protocol. IIV3 contained 15 µg hemagglutinin per strain of A/Michigan/45/2015 (H1N1)pdm09-like virus,
A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus (B/Victoria lineage). IIV4 contained 15 µg hemagglutinin of each of the above strains
plus 15 µg hemagglutinin of B/Phuket/3073/2013-like virus (B/Yamagata lineage). Abbreviations: CI, confidence interval; GMT, geometric mean titer; HAI,
hemagglutination inhibition; IIV4, quadrivalent inactivated influenza vaccine; IIV3, trivalent inactivated influenza vaccine
a The IIV3 formulation did not include the B/Phuket/3073/2013-like virus (B/Yamagata strain)
b Geometric mean of the individual ratios of the post-vaccination (day 21) HAI titer divided by the pre-vaccination (day 0) HAI titer
c Seroconversion was defined as a pre-vaccination (day 0) HAI titer <1:10 and a post-vaccination (day 21) HAI titer ≥1:40, and a significant increase was defined as
a pre-vaccination HAI titer ≥1:10 and a ≥ 4-fold increase in HAI titer
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vaccination with the 2009 adjuvanted pandemic A/H1N1 vac-
cine, which was received by more than one-half of Finland’s
population.34 The high baseline B/Yamagata titers could be
related to the high circulation of this lineage in 2017 − 2018,27
and could have limited the difference in titer increase for this
strain between IIV4 and IIV3. Nonetheless, more than 95% of
IIV4 recipients had titers of 1:40 or higher against each indivi-
dual vaccine strain on day 21.
As reported previously,35 cord blood HAI antibody titers
were higher than those from maternal blood, which indicates
the newborns should have been passively immunized against the
influenza strains of each vaccine. In previous clinical studies,
newborns of IIV3 recipients had higher HAI titers for all vaccine
strains, and were more likely to have titers of 1:40 or higher, than
did newborns of placebo or control vaccine recipients.13,15
Compared with IIV3 recipients, IIV4 recipients did not have
clearly increased cord blood to maternal blood HAI GMT ratios
for the additional B/Yamagata strain, perhaps again due to high
baseline B/Yamagata HAI titers in the population.
The pregnant women vaccinated with IIV4 experienced no
differences in solicited local and systemic reactions, or unso-
licited vaccine-related AEs to those vaccinated with IIV3. The
frequently observed injection site reactions, headache, and
myalgia after vaccination are expected reactions from influ-
enza vaccines, and have been reported in similar proportions
of participants in other studies.13–15,30 Solicited injection site
reactions were more frequently reported in IIV4 recipients
than in IIV3 recipients (90% vs. 81%), though this slight
difference was not considered medically significant.
Moreover, nearly all of the solicited reactions were mild in
intensity and short-lived.
None of the reported pregnancy complications or conge-
nital abnormalities were considered vaccine-related. This is
consistent with the large body of evidence affirming no
increased risk of adverse pregnancy outcomes following
influenza vaccination during pregnancy.9,36,37 The observed
incidence of hip dysplasias (17.1 per 1000) was within the
expected incidence rate for Scandinavian countries
(0.9 − 28 per 1000).38
Our study is the first to evaluate the immunogenicity and
safety of IIV4 specifically in pregnant women. The study was
strengthened by its randomized design and by comparing to
the IIV3 formulation, which has been shown safe and effective
during pregnancy.13–15 However, due to low enrollment, our
study could only report descriptive analyses. The originally
planned, larger sample size should not have considerably
increased the rates of observed rare serious vaccine-related
AEs, given that much larger studies of IIV4,30 and of IIV3 in
pregnant women,13–15 show very low rates of these events.
Our study was also limited by only including pregnant women
in late second or third trimester, whereas the WHO
Figure 2. Maternal and cord blood hemagglutination inhibition (HAI) antibody
titers at delivery. (a) Maternal and cord blood HAI geometric mean titers (GMTs).
(b) GMT ratio: the geometric mean of the individual ratios of the cord blood HAI
titer divided by the maternal HAI titer at delivery. The trivalent inactivated
influenza vaccine (IIV3) contained A/H1N1, A/H3N2, and a strain from the B/
Victoria lineage. The quadrivalent inactivated influenza vaccine (IIV4) contained
each of the above strains plus a strain from the B/Yamagata lineage. Values are
for all subjects completing the study according to protocol who provided blood
and cord blood samples at delivery. For GMT ratios (b), mothers that had twins
were counted twice. Abbreviation: CI, confidence interval.
Table 2. Proportions of subjects experiencing adverse events within 21 days
after vaccination.
IIV4 IIV3
(N = 230) (N = 116)
Event n % (95% CI) n % (95% CI)
Immediate unsolicited AE 0 0.0 (0.0 − 1.6) 0 0.0 (0.0 − 3.1)
Solicited reaction 214 93.0 (88.9 − 96.0) 106 92.2 (85.7 − 96.4)
Solicited injection site
reaction
207 90.0 (85.4 − 93.6) 93 80.9 (72.5 − 87.6)
Solicited systemic
reaction
155 67.4 (60.9 − 73.4) 83 72.2 (63.0 − 80.1)
Unsolicited AE 127 55.2 (48.5 − 61.8) 61 52.6 (43.1 − 61.9)
Vaccine-related 29 12.6 (8.6 − 17.6) 17 14.7 (8.8 − 22.4)
Non-serious 126 54.8 (48.1 − 61.3) 61 52.6 (43.1 − 61.9)
Non-serious vaccine-
related
29 12.6 (8.6 − 17.6) 17 14.7 (8.8 − 22.4)
Injection site non-
serious vaccine-related
9 3.9 (1.8 − 7.3) 4 3.4 (0.9 − 8.6)
Systemic non-serious
vaccine-related
23 10.0 (6.4 − 14.6) 13 11.2 (6.1−18.4)
AE leading to study
discontinuation
0 0.0 (0.0 − 1.6) 0 0.0 (0.0 − 3.1)
Serious AE 2 0.9 (0.1 − 3.1) 0 0.0 (0.0 − 3.1)
Vaccine-related 0 0.0 (0.0 − 1.6) 0 0.0 (0.0 − 3.1)
Death 0 0.0 (0.0 − 1.6) 0 0.0 (0.0 − 3.1)
Abbreviations: AE, adverse event; CI, confidence interval; IIV4, quadrivalent
inactivated influenza vaccine; IIV3, trivalent inactivated influenza vaccine
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recommends influenza vaccination at any stage of pregnancy.1
Nonetheless, other studies have shown IIV3 has a similar
safety profile at other gestational ages.13–15,17 Finally, the
study was conducted only in Finland. Including pregnant
women from other countries might have increased the size
of the study and helped confirm consistency across different
regions.
Consistent with the recognized safety and effectiveness of
IIV3 during pregnancy,1,11,13–15,39 our results support the use
of IIV4 to protect pregnant women against influenza. The high
cord blood HAI antibody titers also suggest maternal immuni-
zation with IIV4 would protect newborns against influenza, at
least as well as IIV3,13,15 via passively acquired antibodies. The
results from this study might encourage healthcare professionals
to recommend IIV4 to pregnant women, for whom vaccination
coverage is often poor due to concerns about influenza vaccine
safety and efficacy during pregnancy.22
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